Keyphrases
Premalignancy
100%
Lung Cancer
100%
5-azacytidine
100%
Bronchial Epithelium
44%
Inhalation
33%
Lung Toxicity
33%
Tumor Suppressor Gene
33%
Re-expression
33%
Phase I Study
22%
Cancer Causes
22%
Early Intervention Strategy
22%
Large Population
22%
Cancer Mortality
22%
Individuals at Risk
22%
Intratracheal
11%
Long-term Programs
11%
Tobacco
11%
Demethylating Agents
11%
Tumor Suppressor
11%
Tobacco Carcinogens
11%
Healthy Lung
11%
Lung
11%
Early Detection System
11%
Optimal Dose
11%
Pharmacodynamics
11%
Human Studies
11%
Carcinogenesis Process
11%
Optimal Biological Dose
11%
Tolerability
11%
Epigenetic Strategies
11%
Methylation Pattern
11%
Public Health
11%
Lung Tumor Development
11%
Non-cytotoxic
11%
Most Common Cause
11%
Route of Administration
11%
Starting Dose
11%
Clinical Benefit
11%
Airway Surface
11%
Clinical Phases
11%
Genetic Damage
11%
Promoter Methylation
11%
Myelodysplasia
11%
Cytotoxic Effect
11%
Clinical Efficacy
11%
Lung Cancer Model
11%
Specific Intent
11%
Fold Increase
11%
Preleukemic
11%
Human Lung Cancer
11%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
11%
Nude Mice
11%
Therapeutic Strategies
11%
Therapeutic Index
11%
Proof of Concept Study
11%
Murine Model
11%
Minimal Effective Dose
11%
Medicine and Dentistry
Precancerous Condition
100%
Azacitidine
100%
Lung Cancer
100%
Bronchial Epithelium
44%
Tumor Suppressor Gene
33%
Pulmonary Toxicity
33%
Lung
22%
Malignant Neoplasm
22%
Target Tissue
22%
Therapeutic Window
11%
Non-Small Cell Lung Cancer
11%
Tumor Suppressor Protein
11%
Methylation
11%
Lung Tumor
11%
Optimal Drug Dose
11%
Early Intervention
11%
Human Study
11%
Minimal Effective Dose
11%
Myelodysplastic Syndrome
11%
Cancer Model
11%
Promoter Region
11%
Genetic Damage
11%
Pharmacodynamics
11%
Carcinogen
11%
Cytotoxicity
11%
Carcinogenesis
11%
Diseases
11%
Pharmacology, Toxicology and Pharmaceutical Science
Azacitidine
100%
Precancer
100%
Lung Cancer
100%
Tumor Suppressor Protein
44%
Lung Toxicity
33%
Malignant Neoplasm
22%
Preclinical Study
22%
Therapeutic Window
11%
Lung Tumor
11%
Cancer Model
11%
Carcinogenesis
11%
Myelodysplastic Syndrome
11%
Minimal Effective Dose
11%
Cytotoxicity
11%
Pharmacodynamics
11%
Tolerability
11%
Nude Mouse
11%
Human Study
11%
Carcinogen
11%
Route of Administration
11%
Diseases
11%